Friday, 20 Apr 2018

You are here

BUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection

Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year. 

The baricitinib pivotal studies include the BEGIN study (early RA; MTX naive), BEACON study (TNF incomplete responders [IR]), BEAM study (MTX-IR) and the BUILD study (DMARD-IR). The latter study results were just published in ARD.

The BUILD study was a phase III, 24-week study of 684 RA patients who had failed at least one DMARD. Patients had to be biologic naive and were randomized to receive either placebo or baricitinib (2 or 4 mg) once daily.  The endpoint was the ACR20 response at week 12 and X-ray (TSS) scores at week 24.

Baricitinib showed a significantly greater ACR20 response at week 12 (4 mg 62% vs placebo 39%, p≤0.001).

Not surprisingly, all secondary endpoints were significantly greater with both baricitinib doses. This included radiographic assessments that showed less structural joint damage at week 24 was reduced with baricitinib versus placebo.

Baricitinib was associated with a decrease in neutrophils and increases in low-density and high-density lipoprotein. There were no differences in SAEs or SIEs in treatment groups. There was one case of tuberculosis and one patient with a non-melanoma skin cancer on baricitinib 4 mg.

The 4 mg baricitinib group yielded the most robust results.  It is unclear from data yet reported what the best or approved dose will be.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

IL-6 Inhibition Most Effective in Polycyclic Systemic JIA

The German Autoinflammatory Disease (AID) registry has studied the effects of the IL-6 inhibitor tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA) patients and shown a clinical response rate of 35% during the first 12 weeks, and inactive disease and/or remission (with medication) in 75% at 12 months.

Rituximab May Halt ILD in Antisynthetase Syndrome Myositis

A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most. 

Anakinra May Attenuate Stroke Outcomes

The journal Stroke has published a trial wherein the use of subcutaneous IL-1Ra (anakinra) was shown to reduce the peripheral inflammatory response in those with an acute ischemic stroke. (Citation source: http://bit.ly/2uoNXEL)

FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis

Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.

The US Food and Drug Administration’s (FDA) convened the Gastrointestinal Drugs Advisory Committee Meeting (GIDAC) to assess Pfizers supplemental new drug application for tofacitinib in adult patients with moderately to severely active ulcerative colitis (UC).

Abatacept Efficacy in JIA

Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.